Weight loss
Hormone therapy plus tirzepatide: 35% more weight loss after menopause — with one caveat worth reading
If you're navigating both menopause and weight, this one caught my eye. A 2026 analysis suggests that adding hormone therapy to tirzepatide — the GLP-1/GIP drug behind Mounjaro and Zepbound — may meaningfully boost weight loss after menopause. It's a genuinely interesting signal, so let me walk through what the study actually showed, and the part that matters just as much as the headline.
The study, published in The Lancet Obstetrics, Gynaecology & Women's Health in early 2026, followed postmenopausal women with overweight or obesity who were taking tirzepatide. It compared those also using menopausal hormone therapy (HT) with those on tirzepatide alone. Over 12 months, the hormone-therapy group lost about 35% more weight — a total bodyweight reduction of –19.2% versus –14.0% (p=0.0023). Put another way, 45% of the hormone-therapy users lost at least a fifth of their bodyweight, compared with 18% of the others. Cardiometabolic markers improved more in the combination group too.
Why might oestrogen make a difference? The leading explanation is that oestrogen influences where the body stores fat and how it handles insulin and appetite signals. As it falls in menopause, weight tends to shift toward the abdomen and metabolism becomes less forgiving — so topping oestrogen back up may simply restore some of the metabolic conditions that make a weight-loss drug work better. That's a plausible mechanism, not a proven one, and this study wasn't designed to prove cause and effect.
That's the caveat I'd underline. This is a retrospective cohort study — it looked back at records of women who happened to be on these treatments, rather than randomly assigning them. Women who choose hormone therapy may differ in ways that also help with weight (they may be more engaged with their health, for instance), and an observational design can't fully rule that out. It shows a strong association, not proof. Tirzepatide's own weight-loss effect is well established from randomised trials — around 20% bodyweight versus roughly 3% on placebo — but the specific hormone-therapy boost still needs a proper randomised trial to confirm.
And the part that doesn't make the headline: rapid weight loss at midlife has a body-composition cost. A meaningful share of the weight lost on any GLP-1 drug can come from muscle as well as fat, and menopause is already a vulnerable time for bone density as oestrogen drops. Losing weight fast, while your bones and muscle are under pressure anyway, is a combination clinicians increasingly flag. It doesn't mean don't do it — it means build in the protective habits from day one: enough protein (roughly 1.2–1.6 g per kg of bodyweight a day), resistance training a couple of times a week, and adequate vitamin D and calcium. None of that is optional if you want to keep the muscle and bone you'll rely on for decades.
What the research says
In a retrospective cohort study of postmenopausal women with overweight or obesity, those using menopausal hormone therapy alongside tirzepatide lost 35% more total bodyweight over 12 months than those on tirzepatide alone (–19.2% vs –14.0%; p=0.0023). 45% of hormone-therapy users achieved at least 20% total bodyweight loss versus 18% of controls, with greater improvement in cardiometabolic markers. Because the design is observational, it demonstrates association rather than causation.
The Lancet Obstetrics, Gynaecology & Women's Health · Retrospective cohort study, 2026 ↗GLP-1-based drugs produce fast weight loss, a portion of which can come from lean mass, and menopause independently accelerates bone-density loss as oestrogen declines. Clinicians therefore recommend pairing these medications with adequate protein (about 1.2–1.6 g/kg/day), regular resistance training, and sufficient vitamin D and calcium to protect muscle and bone during treatment.
Clinical guidance on GLP-1 use, menopause and body composition, 2026 ↗Frequently asked questions
Does this mean I should ask for hormone therapy to lose more weight?
Not on the strength of this study alone. It found a strong association, but it's observational — it can't prove the hormone therapy caused the extra weight loss, and it wasn't a trial. Hormone therapy is a decision that should rest on your menopause symptoms, your timing relative to menopause and your personal risk profile, discussed with your clinician. Better weight loss on a GLP-1 drug, if it holds up, would be a bonus rather than a reason to start.
How do I avoid losing muscle and bone on a GLP-1 drug during menopause?
Plan for it from the start rather than reacting later. The core protections are eating enough protein (roughly 1.2–1.6 g per kg of bodyweight a day), doing resistance training two to three times a week, and making sure your vitamin D and calcium are adequate. These are the same habits that protect bone and muscle through menopause generally — the weight-loss drug just makes them non-negotiable.
The information on this website is educational and is not medical advice. Please consult your doctor if you have any doubts or further questions.